These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 9616366)

  • 1. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.
    Leslie RG
    Immunology; 1999 Jul; 97(3):371-3. PubMed ID: 10447756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
    Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
    Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).
    Marquart HV; Svendsen A; Rasmussen JM; Nielsen CH; Junker P; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Jul; 101(1):60-5. PubMed ID: 7621593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system.
    Marquart HV; Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Scand J Immunol; 1997 Sep; 46(3):246-53. PubMed ID: 9315112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.
    Halkjær L; Troldborg A; Pedersen H; Jensen L; Hansen AG; Hansen TK; Bjerre M; Østergaard JA; Thiel S
    Front Immunol; 2020; 11():774. PubMed ID: 32431705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
    Marquart HV; Rasmussen JM; Leslie RG
    Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
    Zhang MX; Klein B
    Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
    Fridkis-Hareli M; Storek M; Or E; Altman R; Katti S; Sun F; Peng T; Hunter J; Johnson K; Wang Y; Lundberg AS; Mehta G; Banda NK; Michael Holers V
    Mol Immunol; 2019 Jan; 105():150-164. PubMed ID: 30513451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structural basis for complement receptor type 2 (CR2, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras.
    Johnson AA; Mirowski Rosengard A; Skjodt K; Ahearn JM; Leslie RG
    Eur J Immunol; 1999 Dec; 29(12):3837-44. PubMed ID: 10601991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
    Vuagnat BB; Mach J; Le Doussal JM
    Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.